Stiff Generic Competition Awaits These 2 Cancer Blockbusters
Anytime a megablockbuster nears the end of its IP-protected life, plenty of companies will emerge to get a piece of the pie. In this case, Roche has two megablockbusters with a combined $13.5 billion in 2012 sales coming off patent in the next several years. That is bad news for the innovator, but opens a big opportunity for the various companies targeting biosimilars. In fact, a total of 19 trials are under way to develop generic versions of Rituxan and Herceptin. In the following video, Fool contributor Maxx Chatsko tells investors which companies to keep an eye on in the race to unseat Roche.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Stiff Generic Competition Awaits These 2 Cancer Blockbusters originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.